-- 周二盘前，美国股指期货走高，近期人工智能和科技领域的乐观情绪提振了投资者信心，尽管美伊新一轮谈判仍存在不确定性。 道琼斯工业平均指数期货上涨0.5%，标普500指数期货上涨0.2%，纳斯达克指数期货上涨0.3%。 摩根大通(JPM)将标普500指数的年底目标价上调至7600点，理由是人工智能和科技驱动的盈利增长。亚马逊(AMZN)表示，计划向人工智能聊天机器人Claude的开发商Anthropic投资50亿美元，如果达到某些商业里程碑，未来可能追加至多200亿美元的投资。 美国总统唐纳德·特朗普对新一轮和平谈判持乐观态度，而伊朗则表示不会在“威胁的阴影下”进行谈判。两国之间的停火协议将于明日到期。 交易员们关注最新一轮财报，通用电气航空航天公司 (GE) 和联合健康集团 (UNH) 公布的第一季度调整后盈利和营收均有所增长。 油价小幅下跌，近月全球基准北海布伦特原油下跌0.2%，至每桶95.20美元；美国西德克萨斯中质原油下跌0.7%，至每桶88.95美元。 3月份零售销售额增长1.7%，高于彭博社汇总的1.4%的预期增幅（经向上调整后为0.7%）。 美联储主席候选人凯文·沃什的参议院银行委员会听证会定于美国东部时间上午10点举行。 其他国际市场方面，日本日经指数收盘上涨0.9%，香港恒生指数收盘上涨0.5%，中国上证综指收盘上涨0.1%。与此同时，英国富时100指数下跌0.2%，德国DAX指数在欧洲午后交易时段上涨0.4%。 在股票方面，亚马逊股价在盘前交易中上涨2.2%。联合健康集团(UnitedHealth)股价上涨7.4%，此前该公司公布的第一季度调整后盈利和营收均超出分析师预期。丹纳赫(Danaher)股价上涨0.5%，此前该公司公布的第一季度调整后盈利也超出分析师预期。 苹果(AAPL)股价小幅下跌0.7%，此前该公司宣布蒂姆·库克(Tim Cook)计划卸任首席执行官一职，转任执行董事长，硬件工程资深人士约翰·特纳斯(John Ternus)将接任首席执行官。3M(MMM)股价下跌3.7%，尽管该公司第一季度调整后盈利和净销售额均超出分析师预期。
Related Articles
Equities
Canada's Retail Sales Momentum May Fade Later in The Year, Says National Bank
Statistics Canada's advance estimate points to a 0.6% month-over-month nominal increase in March retail sales, said National Bank of Canada after Friday's data.Given the surge in gasoline prices that occurred in the month, this figure heavily reflects higher prices at the pump. As a result, in real terms, retail sales could register a contraction in the final month of Q1, noted the bank.Nonetheless, for the quarter, information received to date indicates that real retail sales could grow at a 4.7% annualized pace, following a 2.0% decline in the previous quarter -- marking the strongest quarterly performance since Q4 2024, stated National Bank.This is all the more impressive as it is occurring against a backdrop of demographic contraction, pointed out the bank.Indeed, the most recent figures from StatsCan indicate that the country's population declined for a second consecutive quarter -- an unprecedented development.As a result, real retail spending per capita is tracking a 5.2% increase in Q1, a rebound from the sluggish prints seen in 2025. Still, National Bank thinks that this momentum could fade fast as the year progresses.As a result of the conflict in the Middle East, households will face an erosion in purchasing power in the coming months. This, combined with a mortgage interest-payment shock and a still fragile labor market, could weigh on discretionary spending going forward, according to the bank.
$$CXY
Australia
Cinemark Likely to Benefit From Release Slate, Wedbush Says
Cinemark (CNK) is set to benefit from a more consistent release slate over the next several quarters and further market share gains, Wedbush said in a Monday note."The summer slate, especially in Q3, is shaping up very nicely," the report said.The note said theater investments, including laser projectors, premium seats and screens, IMAX expansion, and strategic pricing could drive market share gains. It also pointed to other benefits such as new builds and returning cash to shareholders.For its Q1 results due May 1, Wedbush expects Cinemark to post Q1 revenue of $638 million, against consensus of $629 million, and a loss of $0.03 per share, against consensus of $0.16 loss.Wedbush kept its outperform rating and a $37 price target.Price: $29.40, Change: $+0.92, Percent Change: +3.23%
$CNK
Asia Markets
Swiss Market Index Closes Little Changed; Santhera Shares Jump
The blue-chip Swiss Market Index was down 0.03% on Monday's close, as investors gear up for a busy week of corporate updates, economic data prints and key monetary policy decisions.Santhera Pharmaceuticals (SANN.SW) secured a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use to expand the approval of its Duchenne muscular dystrophy drug Agamree to include the treatment of children who are at least two years old. The drug is currently approved for use on patients aged four and above. The Swiss specialty pharmaceutical company's shares gained 8.38% at closing.Meanwhile, RBC Capital Markets reiterated its outperform rating on Lonza Group (LONN.SW), with a price target of 670 francs, amid expectations that the Swiss pharmaceutical manufacturer's upcoming first-quarter update would be "uneventful." At the end of the trading day, the stock was up 1.83%."We do not see the Q1 qualitative update on 8 May to be a major catalyst for the stock now that Vacaville-specific commentary will no longer be provided, and any further weakness in Specialized Modalities should not be a surprise. We have also taken the opportunity to refresh and add to our commercial product (Enflonsia) and pipeline trackers. There has been some clinical progress, but consensus forecasts have been pushed out a little (aggregate peak sales estimates are unchanged)," the research firm said, noting that it views Lonza as an "attractive and undervalued compounding investment story."The local economic news calendar was empty for the day, while the release of the Swiss KOF Economic Barometer and the UBS & CFA Society Switzerland's economic sentiment index for April, as well as the country's March retail sales figures are on the agenda over the coming days. Market watchers are also awaiting the rate decisions of the US Federal Reserve, the European Central Bank, and the Bank of England.
$^SSMI$LONN.SW$SANN.SW